AtaiBeckley (ATAI) EBT (2020 - 2026)
AtaiBeckley (ATAI) posted quarterly EBT of -$29.8 million for Q1 2026, down 13.2% year-over-year from -$34.3 million in Q1 2025, and down 13.2% quarter-over-quarter from -$26.3 million in Q1 2025.
AtaiBeckley (ATAI) EBT (2020 - 2026) Analysis & Trends
AtaiBeckley has reported EBT for 6 years, with the latest figure at -$61.0 million in Q3 2025.
- Quarterly EBT fell 130.39% year-over-year to -$61.0 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was -$154.1 million (down 20.83% YoY) and the FY2024 annual result came in at -$148.4 million, down 277.76% from the prior year.
- EBT for Q1 2026 stood at -$29.8 million, down from -$26.3 million in the prior quarter.
- The five-year high for EBT was -$26.3 million in Q1 2025, with the low at -$29.8 million in Q1 2026.
- A 5-year average of -$30.2 million and a median of -$31.7 million in 2023 frame the typical range for EBT.
- The sharpest annual moves came in 2021 and 2023: EBT sank 841.8% in 2021, then soared 232.33% in 2023.
- Over 5 years, EBT stood at -$48.6 million in 2021, then gained by 19.06% to -$39.3 million in 2022, then soared by 53.41% to -$18.3 million in 2023, then tumbled by 113.89% to -$39.2 million in 2024, then sank by 55.59% to -$61.0 million in 2025.
- According to Business Quant data, EBT over the past three periods registered -$61.0 million, -$27.7 million, and -$26.3 million for Q3 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | AtaiBeckley | 2.69 Bn | 2.69 Bn | - | -60.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -32.48 Mn |
| Mar 31, 2026 | -29.78 Mn |
| Sep 30, 2025 | -60.97 Mn |
| Jun 30, 2025 | -27.65 Mn |
| Mar 31, 2025 | -26.31 Mn |
| Mar 31, 2025 | -26.31 Mn |
| Dec 31, 2024 | -39.18 Mn |
| Sep 30, 2024 | -26.46 Mn |
| Jun 30, 2024 | -57.08 Mn |
| Mar 31, 2024 | -25.68 Mn |
| Dec 31, 2023 | -18.32 Mn |
| Sep 30, 2023 | 43.85 Mn |
| Jun 30, 2023 | -31.66 Mn |
| Mar 31, 2023 | -33.16 Mn |
| Dec 31, 2022 | -39.32 Mn |
| Sep 30, 2022 | -33.13 Mn |
| Jun 30, 2022 | -30.81 Mn |
| Mar 31, 2022 | -31.92 Mn |
| Dec 31, 2021 | -48.58 Mn |
| Sep 30, 2021 | -26.47 Mn |